VIRALEX is an immune-modulatory agent with broad-spectrum antiviral properties. It enhances both innate and adaptive immunity and strengthens the body’s defense response to viral infections
Enhances both innate & adaptive immunity and strengthens body’s immune response to viral infections March 7:
In a landmark development for the treatment of COVID-19, Themis Medicare Ltd. (Themis), a Pharmaceutical company headquartered in Mumbai with a legacy of over 50 years of making new treatment options available, announced the approval of its antiviral drug VIRALEX® by the Drug Controller General of India (DCGI).
As per the results of double-blind randomized controlled trials (RCT), the drug helps in early relief of the clinical symptoms in mild tomoderateCOVID-19 patients. Viralex is effective and well-tolerated in mild to moderate COVID-19, in two Randomized Controlled Clinical Trials conducted on 499 Indian patients.
After detailed deliberation, the drug regulatory authority granted permission to manufacture and market this new drug for restricted emergency use of the drug as an add-on therapy for the treatment of mild and moderate COVID-19.
VIRALEX® would be available on the prescription.
Based on the promising study results, the drug appears to offer immense clinical benefit to the patients in the early stages of COVID-19, thus reducing the load on the healthcare system.
VIRALEX is an immune-modulatory agent with broad-spectrum antiviral properties. It enhances both innate and adaptive immunity and strengthens the body’s defense response to viral infections.
According to Themis, VIRALEX will be manufactured at an EU-GMP-certified facility with the highest safety standards and stringent manufacturing protocols in place, and the medication will be available in the form of a 500 mg tablet at a much more affordable price.
Speaking at the release, Dr. Sachin Patel, Managing Director & CEO of Themis Medicare Ltd. said, “Our endeavor has always been to develop medicines that benefit patients and make healthcare far, far more effective. Given the current scenario of grave health concerns and economic challenges surrounding COVID-19 in India, this is our effort to contribute to the well-being of people of India”.